Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 1, 2015, Pages 98-103

  Akamine, Y ^a,b   Miura, M ^c   Yasui Furukori, N ^d   Ieiri, I ^b   Uno, T ^a  

^a UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c AKITA UNIVERSITY HOSPITAL   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

Author keywords

enantiomer; fexofenadine; organic anion transporting polypeptides; pharmacokinetics; rifampicin; standard dose

Indexed keywords

FEXOFENADINE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; PLACEBO; RIFAMPICIN; ANTIALLERGIC AGENT; CYTOCHROME P450 2B6 INDUCER; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; ENANTIOMER; FEMALE; HUMAN; JAPANESE (PEOPLE); KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; ORAL CLEARANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; JAPAN;

ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2B6 INDUCERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; JAPAN; RIFAMPIN; TERFENADINE;

EID: 84920279362     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12213     Document Type: Article

References (40)

1. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT,. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet, 2003; 40: 819-850.
2. Baciewicz AM, Chrisman CR, Finch CK, Self TH,. Update on rifampin and rifabutin drug interactions. Am J Med Sci, 2008; 335: 126-136.
3. Schuetz EG, Beck WT, Schuetz JD,. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol, 1999; 49: 311-318.
4. Shitara Y,. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet, 2011; 26: 220-227.
5. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K,. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology, 2002; 36: 164-172.
6. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol, 2009; 158: 693-705.
7. Lau YY, Huang Y, Frassetto L, Benet LZ,. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther, 2007; 81: 194-204.
8. Lennernäs H,. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet, 2003 42:; 1141-1160.
9. Bailey DG,. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol, 2010; 70: 645-655.
10. Tapaninen T, Neuvonen PJ, Niemi M,. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol, 2011; 71: 718-726.
11. Xiong H, Carr RA, Locke CS, et al,. Dual effects of rifampin on the pharmacokinetics of atrasentan. J Clin Pharmacol, 2007; 47: 423-429.
12. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J,. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther, 2007; 81: 414-419.
13. Zheng HX, Huang Y, Frassetto LA, Benet LZ,. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther, 2009; 85: 78-85.
14. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brosen K,. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol, 2004; 60: 109-114.
15. Treiber A, Schneiter R, Häusler S, Stieger B,. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos, 2007; 35: 1400-1407.
16. Harrison B, Magee MH, Mandagere A, Walker G, Dufton C, Henderson LS, Boinpally R,. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig, 2010; 30: 875-885.
17. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ,. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther, 2005; 78: 154-167.
18. Product information: Livalo, Kowa Pharmaceutical company, Tokyo, Japan, 2003.
19. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ,. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos, 1998; 19: 455-463.
20. Miura M, Uno T, Tateishi T, Suzuki T,. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality, 2007; 19: 223-227.
21. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB,. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos, 1999; 27: 866-871.
22. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y,. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos, 2008; 36: 663-669.
23. Tateishi T, Miura M, Suzuki T, Uno T,. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol, 2008; 65: 693-700.
24. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T,. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol, 2009; 67: 535-540.
25. Akamine Y, Miura M, Yasui-Furukori N, Kojima M, Uno T,. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol, 2012; 73: 478-481.
26. Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T,. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica, 2010; 40: 782-789.
27. Kusuhara H, Miura M, Yasui-Furukori N, et al,. Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. Drug Metab Dispos, 2013; 41: 206-213.
28. Akamine Y, Miura M, Komori H, et al,. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. Eur J Clin Pharmacol, 2014; 70: 1087-1095.
29. Product information: Rifadin, Daiichi-Sankyo Pharmaceutical, Tokyo, Japan, 2009.
30. Miura M, Uno T, Tateishi T, Suzuki T,. Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal, 2007; 43: 741-745.
31. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD,. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther, 2001; 69: 114-121.
32. Acocella G, Pagani V, Marchetti M, Baroni GC, Nicolis FB,. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy, 1971; 16: 356-370.
33. Komoto C, Nakamura T, Sakaeda T, et al,. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet, 2006; 21: 126-132.
34. Nakanishi T, Tamai I,. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet, 2012; 27: 106-121.
35. Imanaga J, Kotegawa T, Imai H, et al,. The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics, 2011; 21: 84-93.
36. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB,. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther, 2002; 71: 11-20.
37. Glaeser H, Bailey DG, Dresser GK, et al,. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther, 2007; 81: 362-370.
38. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB,. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res, 2008; 68: 9338-9347.
39. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T,. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther, 2005; 77: 17-23.
40. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y,. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos, 2006; 34: 743-747.